# Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care

> **NCT05088928** · PHASE2 · UNKNOWN · sponsor: **Scotmann Pharmaceuticals** · enrollment: 40 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT05088928
- **Lead sponsor:** Scotmann Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088928, "Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05088928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*